Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 54.4% in August

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a large decrease in short interest in August. As of August 31st, there was short interest totaling 5,707 shares, a decrease of 54.4% from the August 15th total of 12,512 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average trading volume of 16,436 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Alaunos Therapeutics Price Performance

Alaunos Therapeutics stock opened at $1.51 on Monday. The company’s fifty day simple moving average is $1.88 and its 200-day simple moving average is $2.43. Alaunos Therapeutics has a 12 month low of $1.50 and a 12 month high of $4.59. The stock has a market cap of $3.84 million, a P/E ratio of -0.79 and a beta of -0.97.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.41) earnings per share for the quarter.

Institutional Investors Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new stake in Alaunos Therapeutics stock. HRT Financial LP acquired a new position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned approximately 0.54% of Alaunos Therapeutics at the end of the most recent quarter. Institutional investors own 27.72% of the company’s stock.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.